The ROP platform is very broad with applications in infectious disease as well as oncology, in diagnostics as well as therapeutics and also for applications in animal health.
Some diagnostic indications have been licensed to Changzhou Biotech in China who recently announced regulatory approval in China for an ROP based diagnostic for Tuberculosis. In addition, OVM’s largest shareholder Dx&Vx of South Korea recently licenced lead vaccine OVM-200 for clinical development in S. Korea, China, and India.
The AMR test will fulfil a real need in a growing market. OVM is looking for partners to commercialise the kit.
OVM is open to licensing other diagnostic applications of the ROP technology, infectious disease applications and the use of the ROP technology for animal health, and welcomes enquiries.
OVM is also interested in collaborating with Pharmaceutical companies that can provide checkpoint inhibitors suitable for combination with ROP vaccines. In Phase 2 trials.